BioNTech (NASDAQ:BNTX) Posts Earnings Results, Beats Estimates By $2.07 EPS

BioNTech (NASDAQ:BNTX) posted its earnings results on Monday. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07, Briefing.com reports. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the prior year, the business posted $0.73 EPS. The firm’s revenue was up 38.9% compared to the same quarter last year. BioNTech updated its FY 2024 guidance to EPS.

BioNTech Stock Performance

BioNTech stock traded down $4.33 during trading on Wednesday, hitting $106.64. The stock had a trading volume of 1,215,773 shares, compared to its average volume of 784,106. The stock’s 50 day moving average is $110.63 and its two-hundred day moving average is $96.23. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The stock has a market cap of $25.36 billion, a price-to-earnings ratio of -49.10 and a beta of 0.26. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01.

Analysts Set New Price Targets

A number of analysts have commented on BNTX shares. JPMorgan Chase & Co. decreased their price objective on BioNTech from $125.00 to $124.00 and set a “neutral” rating for the company in a report on Monday. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and increased their price target for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. HC Wainwright lifted their price objective on shares of BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, October 7th. TD Cowen reduced their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research note on Tuesday. Finally, Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $134.69.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.